Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia

Ruben A. Mesa, Alfonso Quintás-Cardama, Srdan Verstovsek

Research output: Contribution to journalArticle

Abstract

Myelofibrosis with myeloid metaplasia (MMM) is currently classified as a classic (ie, BCR-ABL-negative) myeloproliferative disorder characterized by anemia, multiorgan extramedullary hematopoiesis, constitutional symptoms, and premature death from either leukemic transformation or other disease complications. Stem cell transplantation can be curative, but many patients either are not appropriate candidates or do not choose to accept the significant risks associated with transplantation. Current pharmacologic therapy has been beneficial mainly in terms of palliating disease-associated cytopenias, constitutional symptoms, splenomegaly, and other organ damage from excess myeloproliferation. Novel treatment strategies are under investigation, including targeted inhibition of JAK2 V617F, the activating tyrosine kinase point mutation present in about half of patients with MMM. In this article, we review both the old and new pharmacologic options for MMM.

Original languageEnglish (US)
Pages (from-to)25-33
Number of pages9
JournalCurrent Hematologic Malignancy Reports
Volume2
Issue number1
DOIs
StatePublished - Jan 2007

Fingerprint

Primary Myelofibrosis
Investigational Therapies
Drug Therapy
Extramedullary Hematopoiesis
Myeloproliferative Disorders
Premature Mortality
Splenomegaly
Stem Cell Transplantation
Point Mutation
Protein-Tyrosine Kinases
Anemia
Transplantation
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia. / Mesa, Ruben A.; Quintás-Cardama, Alfonso; Verstovsek, Srdan.

In: Current Hematologic Malignancy Reports, Vol. 2, No. 1, 01.2007, p. 25-33.

Research output: Contribution to journalArticle

Mesa, Ruben A. ; Quintás-Cardama, Alfonso ; Verstovsek, Srdan. / Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia. In: Current Hematologic Malignancy Reports. 2007 ; Vol. 2, No. 1. pp. 25-33.
@article{0e75fc8305d346a78d68e39f9dbea64e,
title = "Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia",
abstract = "Myelofibrosis with myeloid metaplasia (MMM) is currently classified as a classic (ie, BCR-ABL-negative) myeloproliferative disorder characterized by anemia, multiorgan extramedullary hematopoiesis, constitutional symptoms, and premature death from either leukemic transformation or other disease complications. Stem cell transplantation can be curative, but many patients either are not appropriate candidates or do not choose to accept the significant risks associated with transplantation. Current pharmacologic therapy has been beneficial mainly in terms of palliating disease-associated cytopenias, constitutional symptoms, splenomegaly, and other organ damage from excess myeloproliferation. Novel treatment strategies are under investigation, including targeted inhibition of JAK2 V617F, the activating tyrosine kinase point mutation present in about half of patients with MMM. In this article, we review both the old and new pharmacologic options for MMM.",
author = "Mesa, {Ruben A.} and Alfonso Quint{\'a}s-Cardama and Srdan Verstovsek",
year = "2007",
month = "1",
doi = "10.1007/s11899-007-0004-4",
language = "English (US)",
volume = "2",
pages = "25--33",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",
number = "1",

}

TY - JOUR

T1 - Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia

AU - Mesa, Ruben A.

AU - Quintás-Cardama, Alfonso

AU - Verstovsek, Srdan

PY - 2007/1

Y1 - 2007/1

N2 - Myelofibrosis with myeloid metaplasia (MMM) is currently classified as a classic (ie, BCR-ABL-negative) myeloproliferative disorder characterized by anemia, multiorgan extramedullary hematopoiesis, constitutional symptoms, and premature death from either leukemic transformation or other disease complications. Stem cell transplantation can be curative, but many patients either are not appropriate candidates or do not choose to accept the significant risks associated with transplantation. Current pharmacologic therapy has been beneficial mainly in terms of palliating disease-associated cytopenias, constitutional symptoms, splenomegaly, and other organ damage from excess myeloproliferation. Novel treatment strategies are under investigation, including targeted inhibition of JAK2 V617F, the activating tyrosine kinase point mutation present in about half of patients with MMM. In this article, we review both the old and new pharmacologic options for MMM.

AB - Myelofibrosis with myeloid metaplasia (MMM) is currently classified as a classic (ie, BCR-ABL-negative) myeloproliferative disorder characterized by anemia, multiorgan extramedullary hematopoiesis, constitutional symptoms, and premature death from either leukemic transformation or other disease complications. Stem cell transplantation can be curative, but many patients either are not appropriate candidates or do not choose to accept the significant risks associated with transplantation. Current pharmacologic therapy has been beneficial mainly in terms of palliating disease-associated cytopenias, constitutional symptoms, splenomegaly, and other organ damage from excess myeloproliferation. Novel treatment strategies are under investigation, including targeted inhibition of JAK2 V617F, the activating tyrosine kinase point mutation present in about half of patients with MMM. In this article, we review both the old and new pharmacologic options for MMM.

UR - http://www.scopus.com/inward/record.url?scp=34250691943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250691943&partnerID=8YFLogxK

U2 - 10.1007/s11899-007-0004-4

DO - 10.1007/s11899-007-0004-4

M3 - Article

C2 - 20425385

AN - SCOPUS:34250691943

VL - 2

SP - 25

EP - 33

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

IS - 1

ER -